GSK

As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade. Central to our success are our people: experts in science, technology, manufacturing and commercialisation... 66,800 GSK people across 70 countries worldwide 33 manufacturing sites £7.5bn Total R&D expense in 2025 18,000 suppliers working directly with GSK ...who are identifying, researching, developing and delivering... Specialty Medicines Our specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. Many are first or best-in-class. General Medicines Our broad portfolio of general medicines, from inhalers for asthma and COPD to antibiotics, improve life for millions of people around the world. Many are market leaders. Vaccines We have one of the broadest portfolios of vaccines in the industry, targeting infectious diseases at every stage of life, helping to protect people from meningitis, shingles, RSV, hepatitis and many more. We prevent and treat disease with specialty medicines, vaccines and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas – respiratory, immunology and inflammation; oncology; HIV; and infectious diseases – to impact health at scale. We operate responsibly for all our stakeholders.